Biphosphonate-induced radiographic changes in two pediatric patients with rheumatic diseases

2004 ◽  
Vol 33 (12) ◽  
pp. 732-736 ◽  
Author(s):  
Joao L. Fernandes ◽  
Sergio L. Viana ◽  
Arthemizio L. Rocha ◽  
Maria C. Ribeiro ◽  
Luis C. Castro
Keyword(s):  
Rheumatic Diseases ◽  
Pediatric Patients ◽  
Radiographic Changes

scholarly journals School attendance and patterns, special services and special needs in pediatric patients with rheumatic diseases: Results of a multicenter study

1990 ◽  
Vol 3 (4) ◽  
pp. 196-203 ◽  
Author(s):  
Daniel J. Lovell ◽  
Balu Athreya ◽  
Helen M. Emery ◽  
Donna L. Gibbas ◽  
Joseph E. Levinson ◽  
...  
Keyword(s):  
Special Needs ◽  
Rheumatic Diseases ◽  
Multicenter Study ◽  
Pediatric Patients ◽  
School Attendance ◽  
Special Services

scholarly journals High Prevalence of Antinuclear Antibodies in Children with Thyroid Autoimmunity

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Maria Segni ◽  
Ida Pucarelli ◽  
Simona Truglia ◽  
Ilaria Turriziani ◽  
Chiara Serafinelli ◽  
...  
Keyword(s):  
Autoimmune Diseases ◽  
Rheumatic Diseases ◽  
Antinuclear Antibodies ◽  
Pediatric Patients ◽  
Thyroid Autoimmunity ◽  
Disease Onset ◽  
Nuclear Antigen ◽  
Chronic Lymphocytic Thyroiditis ◽  
Autoimmune Thyroid Diseases ◽  
Autoimmune Thyroid

Background. Antinuclear antibodies (ANA) are a hallmark of many autoimmune diseases and can be detected many years before disease onset. Autoimmune thyroid diseases (AITD) are frequently associated with other organ- and non-organ-specific autoimmune disorders.Objectives. To assess the prevalence of ANA in pediatric patients with AITD and their clinical correlations.Methods. Ninety-three consecutive pediatric patients with AITD were enrolled (86 children with chronic lymphocytic thyroiditis and 7 with Graves’ disease). ANA, anti-double DNA (anti-dsDNA) antibodies, anti-extractable nuclear antigen (anti-ENA), anti-cyclic citrullinated peptide antibodies (anti-CCP), and rheumatoid factor (RF) was obtained. Signs and symptoms potentially related to rheumatic diseases in children were investigated by a questionnaire.Results. ANA positivity was found in 66/93 children (71%), anti-ENA in 4/93 (4.3%), anti-dsDNA in 1/93 (1.1%), RF in 3/93 (3.2%), and anti-CCP in none. No significant differences were found between the ANA-positive and ANA-negative groups with respect to age, sex, L-thyroxine treatment, or prevalence of other autoimmune diseases. Overall, parental autoimmunity was found in 23%.Conclusions. ANA positivity was demonstrated in 71% of children with AITD. ANA positivity was not related to overt immune-rheumatic diseases. However, because the positivity of ANA can occur even many years before the onset of systemic autoimmune diseases, prospective studies are warranted.

scholarly journals Outcomes of COVID-19 in a cohort of pediatric patients with rheumatic diseases

2021 ◽  
Author(s):  
Diana Sofia Villacis-Nunez ◽  
Christina A. Rostad ◽  
Kelly Rouster-Stevens ◽  
Arezou Khosroshahi ◽  
Shanmuganathan Chandrakasan ◽  
...  
Keyword(s):  
Rheumatic Disease ◽  
Rheumatic Diseases ◽  
Pediatric Patients ◽  
Univariate Analysis ◽  
Case Series ◽  
Hospitalized Patients ◽  
High Dose ◽  
High Dose Corticosteroid ◽  
Severe Immunosuppression ◽  
Dose Corticosteroid

Abstract Background There are few reports of COVID-19 in pediatric patients with rheumatic diseases. This study describes the clinical presentation and outcomes of COVID-19 in this population. Methods We analyzed a single-center case series of pediatric patients with rheumatic diseases and laboratory-confirmed COVID-19. Demographic, baseline and COVID-19 associated clinical features were compared between ambulatory and hospitalized patients using univariate analysis. Results Forty cases were identified: 32 (80%) in the ambulatory group and 8 (20%) hospitalized. Older age (median age 18 years vs 16 years; p = 0.01) and African American race (OR 8.42; 95% CI [1.20-101.69]; p = 0.01) predominated in hospitalized patients. Systemic lupus erythematosus (OR 6.77; 95% CI [1.01–56.71]; p = 0.02), medium/high-dose corticosteroid use (OR 10.62; 95% CI [1.46–99.57]; p = 0.008), mycophenolate use (OR 11.91; 95% CI [1.64-149.35]; p = 0.005), and severe immunosuppression (OR 16.83; 95% CI [1.74-861.43]; p = 0.004) were associated with increased odds of hospitalization. Patients with fever (OR 11.91; 95% CI [1.64-149.35]; p = 0.004), dyspnea (OR 16.51; CI [1.10-998.37]; p = 0.02), and myalgias (OR 13.40; 95% CI [1.43-194.56)]; p = 0.009) were more commonly encountered in the hospitalized group. Rheumatic disease flares were almost exclusive to hospitalized patients (OR 42.13; 95% CI [3.40-2463.87]; p < 0.001).. All patients recovered. Conclusions Medium/high-dose corticosteroid use, mycophenolate use, and severe immunosuppression were risk factors for hospitalization. Fever, dyspnea and myalgias were high-risk symptoms. The type of rheumatic disease, as well as disease flare could be contributing factors to the need for hospitalization.

scholarly journals Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases

2021 ◽  
Author(s):  
Daniel Clemente ◽  
Clara Udaondo ◽  
Jaime de Inocencio ◽  
Juan Carlos Nieto ◽  
Pilar Galan del Rio ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hospital Admission ◽  
Rheumatic Diseases ◽  
Pediatric Patients ◽  
Musculoskeletal Diseases ◽  
Severe Disease ◽  
Tertiary Hospital ◽  
Multivariable Logistic Regression Model ◽  
Symptomatic Disease ◽  
Moderate Disease

Background: This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in pediatric patients with rheumatic and musculoskeletal diseases (RMD) and identify the risk factors associated with symptomatic or severe disease defined as hospital admission, intensive care admission or death. Methods: An observational longitudinal study was conducted during the first year of pandemic SARS-CoV-2 (1st March 2020 to 1st March 2021). All pediatric patients attended at the rheumatology outpatient clinic of six tertiary hospital in Madrid, Spain, with a medical diagnosis of RMD and COVID-19 were included. Main outcomes were symptomatic disease and hospital admission. The covariates were sociodemographic, clinical, and treatments. We ran a multivariable logistic regression model to assess risk factors for outcomes. Results: The study population included 77 pediatric patients. Mean age was 11.88 (4.04) years Of these, 30 patients were asymptomatic, 41 had a mild or moderate disease and other 6 patients (7.79%) required hospital admission related to COVID-19. The median length of stay was 5 (2-20) days and there was no death. Previous comorbidities increased the risk for symptomatic disease and hospital admission. Compared with outpatients, the factor independently associated with hospital admission was the use of glucocorticoids (OR 1.08; p=0.00). No statistically significant findings for symptomatic COVID-19 were found in the final model. Conclusion: Our data found no differences in COVID-19 outcomes between children-onset rheumatic diseases. Our results suggest that associated comorbidities and being in treatment with glucocorticoids increase the risk of hospital admission.

scholarly journals Anthropometric Assessment and lipid metabolism biomarkers of Parents of Pediatric Patients with Chronic Rheumatic Diseases

2021 ◽  
Author(s):  
Lucila Pereira ◽  
Ágatha Nogueira Previdelli ◽  
Rosana Gomes de Torres Rossi ◽  
Wellington Douglas Rodrigues ◽  
Nicole Carvalho Xavier Micheloni da Silva ◽  
...  
Keyword(s):  
Lipid Metabolism ◽  
Rheumatic Diseases ◽  
Pediatric Patients ◽  
Anthropometric Assessment ◽  
Chronic Rheumatic Diseases

scholarly journals The Art of Transitioning Pediatric Patients with Rheumatic Diseases to Adult Rheumatologists

2016 ◽  
Vol 27 (2) ◽  
pp. 55-58
Author(s):  
Florence Kanakoudi-Tsakalidou ◽  
Polyxeni Pratsidou-Gertsi
Keyword(s):  
Rheumatic Diseases ◽  
Pediatric Patients

A170: Neoplasms in Pediatric Patients with Rheumatic Diseases Exposed to Biologics-A Quarternary Centre's Experience

2014 ◽  
Vol 66 ◽  
pp. S220-S221 ◽  
Author(s):  
Rachana P Hasija ◽  
Earl D. Silverman ◽  
Stephanie Cho ◽  
Lillia Fung ◽  
Susanne M. Benseler ◽  
...  
Keyword(s):  
Rheumatic Diseases ◽  
Pediatric Patients

scholarly journals AB0981 VALIDATION OF THE CAREGIVERS QUESTIONNAIRE (IMPACT OF PEDIATRIC RHEUMATIC DISEASES ON CAREGIVERS MULTIASSESSMENT QUESTIONNAIRE) IN PEDIATRIC RHEUMATIC DISEASES

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1784.3-1785
Author(s):  
B. Fortuna ◽  
F. García-Rodríguez ◽  
N. Rubio ◽  
A. V. Villlarreal ◽  
E. Faugier ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Pediatric Patients ◽  
External Validation ◽  
Yale University ◽  
Redes Sociales ◽  
Link Type ◽  
Development And Validation ◽  
The Impact

Background:The CAREGIVERS questionnaire is used as a multidimension screening instrument for burden of caregivers, it allows to examine the impact of juvenile idiopathic arthritis (JIA) on several areas of the caregiver’s life, looking for specific concerns and needs in which treatment could be required. This instrument has shown a good understanding among participants, reliability and consistency to measure the psychosocial and economic impact on primary caregivers of patients with JIA.Objectives:The aim of this study is to validate CAREGIVERS questionnaire with the most common pediatric rheumatic diseases, such as JIA, systemic lupus erythematosus (SLE) and juvenile dermatomyositis (JDM).Methods:The external validation phase of the constructed questionnaire will be carried out following Feinstein’s clinimetric and psychometrics methodology, to measure the impact of the disease on the caregiver and create a risk profile for treatment detachment.Results:A total of 200 questionnaires are applied to caregivers of pediatric patients with rheumatic diseases: 109 caregivers of patients with JIA, 28 caregivers of patients with DMJ and 63 caregivers of patients with SLE. When analyzing all the questions together, a general Cronbach’s alpha of 0.6751 was obtained (Table 1).Table 1.External validation of the QuestionnaireDimensionNumero de ÍtemsAlfa de CronbachI. Impacto Emocional60.5669II. Impacto Social30.47IIIA. Impacto Financiero40.6736IIIB. Impacto Laboral30.3151IV. Impacto Familiar50.4948V. Impacto en la Relación entre Cuidador-paciente1NAVI. Impacto en la relación de pareja1NAVII. Impacto en la Religión/Creencias/Espiritualidad1NAVIII. Impacto de las Redes Sociales40.6642Total280.6751Conclusion:The CAREGIVERS questionnaire showed to be validated to assess the impact of pediatric rheumatic diseases.References:[1]Keppeke, L.d., Molina, J., Miotto e Silva, V.B.et al.Psychological characteristics of caregivers of pediatric patients with chronic rheumatic disease in relation to treatment adherence.Pediatr Rheumatol16,63 (2018).https://doi.org/10.1186/s12969-018-0280-7[2]Cohen EM, Morley-Fletcher A, Mehta DH, Lee YC. A systematic review of psychosocial therapies for children with rheumatic diseases. Pediatr Rheumatol [Internet]. Pediatric Rheumatology; 2017;15(1):6. Available from:http://ped-rheum.biomedcentral.com/articles/10.1186/s12969-016-0133-1.[3]Torres-Made, M.D., Peláez-Ballestas, I., García-Rodríguez, F.et al.Development and validation of the CAREGIVERS questionnaire: multi-assessing the impact of juvenile idiopathic arthritis on caregivers.Pediatr Rheumatol18,3 (2020).https://doi.org/10.1186/s12969-020-0400-z[4]Feinstein AR. Clinimetrics. New Haven: Yale University Press, 1987.Disclosure of Interests:None declared

scholarly journals Challenges in Diagnosing COVID-19 Related Disease in Pediatric Patients With Rheumatic Disease

2021 ◽  
Author(s):  
Seher Şener ◽  
Özge Başaran ◽  
Sibel Laçinel Gürlevik ◽  
Ümmüşen Kaya Akça ◽  
Erdal Atalay ◽  
...  
Keyword(s):  
Rheumatic Disease ◽  
Rheumatic Diseases ◽  
Pediatric Patients ◽  
Juvenile Dermatomyositis ◽  
Systemic Juvenile Idiopathic Arthritis ◽  
Severe Condition ◽  
Delay In Diagnosis ◽  
Systemic Jia ◽  
Mediterranean Fever ◽  
Inflammatory Syndrome

Abstract Objectives Multisystem inflammatory syndrome in children (MIS-C) is a rare but severe condition associated with coronavirus disease 2019 (COVID-19). Here we aimed to raise awareness for the symptoms of MIS-C in patients with rheumatic diseases, emphasizing the challenges of the differential features. Methods We retrospectively evaluated the demographic and clinical characteristics, laboratory and imaging findings, treatments, and outcomes of six MIS-C patients with previous rheumatic disease. Results Three of the patients had familial Mediterranean fever (FMF), one had juvenile dermatomyositis (JDM), one had systemic juvenile idiopathic arthritis (JIA), and another patient had oligoarticular JIA. All FMF patients presented with fever and abdominal pain, two also had chest pain. The patient with systemic JIA presented with fever, rash, and myalgia. All patients had elevated inflammatory markers and high d-dimer levels. Chest imaging of two FMF patients showed infiltrations compatible with pneumonia. One FMF patient had mildly decreased systolic functions with a shortening fraction of 48% in his echocardiography. Intravenous immunoglobulin and methylprednisolone were administered to all patients. Anakinra was given to four patients. Conclusions Clinical and laboratory signs of MIS-C may overlap with the findings of various rheumatic diseases, and this may cause a delay in diagnosis.

Sign in / Sign up

Export Citation Format

Share Document